RTSN.US Retension Pharmaceuticals, Inc. Common Stock

Healthcare Biotechnology USA Stocks
11.46 USD
Close of Nov 17, 2026
9.66 3,150
Market cap
USD 95.5M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is RTSN.US undervalued?

Graham number

The Graham number of Retension Pharmaceuticals, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Retension Pharmaceuticals, Inc. Common Stock fundamental analysis

No fundamental analysis for Retension Pharmaceuticals, Inc. Common Stock yet.

Retension Pharmaceuticals, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Retension Pharmaceuticals, Inc. Common Stock

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascula…

Full company profile